BEDFORD, Mass., Jan. 13 /PRNewswire/ -- Toxikon, a successful, 30-year old preclinical research organization with highly diversified capabilities headquartered in the Greater Boston area, announces that Joseph Pav, Ph.D. has joined the firm to direct the continued growth of the preclinical and clinical bioanalytical services unit. Dr. Pav brings a wealth of knowledge and experience to the organization from his prior roles in method development, validation, analysis, and automation. His prior experience included senior scientific and management roles at Purdue Frederick, Boehringer Ingelheim, Wyeth Research, and PPDI.
Toxikon Corporation, with facilities in the US and Belgium, is ISO/IEC 17025 accredited and registered with the U.S. FDA and Japanese MHLW. The company performs in vivo, analytical, and in vitro testing for the pharmaceutical, biotechnology, and medical device sectors. Services include toxicology (acute, subchronic, and chronic toxicity, reproductive toxicity, genetic toxicology, and carcinogenicity), pharmacokinetics, toxicokinetics, bioavailability, ADME, chemical characterization, impurities analysis and synthesis, bioanalytical, microbiology, and full in vitro toxicology and immunology services. The company has over 1,000 clients in 20 countries worldwide.
SOURCE Toxikon Corporation